The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2020-01-02
• Target enrollment: 0
• Participant gender: Male

Summary

This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-BPH1, a scientific Chinese medicine powder prescription, on patients with benign prostatic hyperplasia.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Criteria

Inclusion Criteria:

• Patients who have been diagnosed with benign prostatic hyperplasia by a urologist

• Have been treated with conventional first-line western medicine for more than three months

• Patients with moderate to severe benign prostatic hyperplasia (IPSS score >12 points)

• Participate voluntarily in the study

Exclusion Criteria:

• At the same time, use other Chinese herbal medicines or alternative medicine (including drugs and acupuncture) for more than one month.

• Syphilis, gonorrhea and other sexually transmitted diseases or urinary tract infections

• Urinary tract stones, prostate cancer, bladder cancer or acute and chronic renal failure

• Congenital abnormalities such as bladder neck fibrosis, interstitial cystitis or urethral stricture

• A history of genital trauma or surgery affecting the muscle or nervous system

• Patients with upper urinary tract obstruction, renal edema, etc. affecting renal function

• Unable to sign a consent form or unable to communicate with researchers